PE20011118A1 - (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto - Google Patents
(+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuestoInfo
- Publication number
- PE20011118A1 PE20011118A1 PE2001000041A PE2001000041A PE20011118A1 PE 20011118 A1 PE20011118 A1 PE 20011118A1 PE 2001000041 A PE2001000041 A PE 2001000041A PE 2001000041 A PE2001000041 A PE 2001000041A PE 20011118 A1 PE20011118 A1 PE 20011118A1
- Authority
- PE
- Peru
- Prior art keywords
- chloro
- methyl
- compound
- alkyl
- cyclopropylmetil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- -1 3-CHLORO-PHENYL Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 238000000926 separation method Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 abstract 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 abstract 1
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 abstract 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000023715 cellular developmental process Effects 0.000 abstract 1
- 229950008696 farnesil Drugs 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A (+)-6-[AMINO-(6-CLORO-PIRIDIN-3-IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-4-(3-CLORO-FENIL)-1-CICLOPROPILMETIL-1H-QUINOLEIN-2-ONA. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE ADEMAS AGENTE QUIMIOTERAPICO O INHIBIDORES DE METALOPROTEASA MMP2; INHIBIDORES DE MMP9, INHIBIDORES DE TRANSDUCCION DE SENALES, AGENTES ANTIPROLIFERATIVOS, AGENTES CAPACES DE BLOQUEAR CTL4; UN METODO PARA SEPARAR ENANTIOANMEROS (+) Y (-) DEL COMPUESTO DE FORMULA I DE LA MEZCLA RACEMICA, DONDE; R1 ES H, ALQUILO C1-C10; R2 ES HALO, CIANO, COOR15; R3 - R7 SON H, ALQUILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS; Z ES HETEROCICLO AROMATICO DE 4-10 MIEMBROS; R9 ES -(CR13R14)t(IMIDAZOLILO), R9 ES (CR13R14)t(PIRIDINILO); R12 ES H, ALQUILO C1-C10, (CR13R14)t(CICLOALQUILO C3-C10), ENTRE OTROS; R13 Y R14 SON H, ALQUILO C1-C10; t ES 0-5; q ES 1-5; R15 NO ES H, R12; n ES 1-3 . UN METODO PARA SINTETIZAR ENANTIOMEROS (+), (-). EL COMPUESTO INHIBE FARNESIL TRANSFERASA ASI COMO EL DESARROLLO CELULAR ANORMAL Y PUEDE SER UTIL EN EL TRATAMIENTO DE CANCER DE PULMON, HUESO, PANCREAS, PIEL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17771800P | 2000-01-21 | 2000-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011118A1 true PE20011118A1 (es) | 2001-11-06 |
Family
ID=22649709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000041A PE20011118A1 (es) | 2000-01-21 | 2001-01-17 | (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6479513B2 (es) |
| EP (1) | EP1248782A1 (es) |
| JP (2) | JP2003520796A (es) |
| AR (1) | AR029792A1 (es) |
| AU (1) | AU2001214087A1 (es) |
| BR (1) | BR0016986A (es) |
| CA (1) | CA2398353C (es) |
| CO (1) | CO5271702A1 (es) |
| GT (1) | GT200100008A (es) |
| HN (1) | HN2000000266A (es) |
| MX (1) | MXPA02007153A (es) |
| MY (1) | MY126069A (es) |
| PA (1) | PA8508101A1 (es) |
| PE (1) | PE20011118A1 (es) |
| SV (1) | SV2002000291A (es) |
| TN (1) | TNSN01009A1 (es) |
| WO (1) | WO2001053289A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| ES2328225T3 (es) | 2000-11-21 | 2009-11-11 | Janssen Pharmaceutica Nv | Derivados benzoheterociclicos inhibidores de la farnesil-transferasa. |
| WO2002051835A1 (en) | 2000-12-27 | 2002-07-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| WO2003006006A1 (en) * | 2001-07-09 | 2003-01-23 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
| ES2323265T3 (es) | 2001-12-19 | 2009-07-10 | Janssen Pharmaceutica Nv | Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa. |
| WO2003080058A1 (en) | 2002-03-22 | 2003-10-02 | Janssen Pharmaceutica. N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
| CA2481480C (en) | 2002-04-15 | 2011-04-12 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| EA008501B1 (ru) * | 2002-12-19 | 2007-06-29 | Пфайзер Инк. | 2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний |
| EP1740184A1 (en) * | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
| US7524961B2 (en) | 2004-05-03 | 2009-04-28 | Janssen Pharmaceutica, N.V. | Diastereoselective addition of lithiated N-methylimidazole on sulfinimines |
| WO2005105784A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
| ES2346986T3 (es) | 2004-05-03 | 2010-10-22 | Janssen Pharmaceutica Nv | Proceso de sintesis diastereoselectiva con 6-bromo-4-(3-clorofenil)-2-methoxi-quinolina. |
| GEP20094845B (en) * | 2004-08-26 | 2009-11-25 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
| EP1786785B9 (en) | 2004-08-26 | 2013-05-22 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
| DK1926996T3 (da) | 2005-09-20 | 2012-01-23 | Osi Pharmaceuticals Llc | Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere |
| WO2007075923A2 (en) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| RU2528884C2 (ru) | 2006-08-21 | 2014-09-20 | Ф.Хоффманн-Ля Рош Аг | Лечение опухолей с помощью антитела к vegf |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| JP2012508768A (ja) | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
| EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| KR20180100125A (ko) | 2015-12-03 | 2018-09-07 | 아지오스 파마슈티컬스 아이엔씨. | Mtap 널 암을 치료하기 위한 mat2a 억제제 |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| HU221227B1 (en) * | 1995-12-08 | 2002-08-28 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use |
| IL141239A0 (en) | 1998-08-27 | 2002-03-10 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
| JP4090200B2 (ja) * | 1999-02-11 | 2008-05-28 | ファイザー・プロダクツ・インク | 抗癌薬として有用なヘテロアリール置換キノリン−２−オン誘導体 |
| HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
-
2000
- 2000-11-27 HN HN2000000266A patent/HN2000000266A/es unknown
- 2000-11-29 EP EP00976213A patent/EP1248782A1/en not_active Withdrawn
- 2000-11-29 AU AU2001214087A patent/AU2001214087A1/en not_active Abandoned
- 2000-11-29 CA CA002398353A patent/CA2398353C/en not_active Expired - Fee Related
- 2000-11-29 WO PCT/IB2000/001769 patent/WO2001053289A1/en not_active Ceased
- 2000-11-29 MX MXPA02007153A patent/MXPA02007153A/es active IP Right Grant
- 2000-11-29 BR BR0016986-2A patent/BR0016986A/pt not_active Application Discontinuation
- 2000-11-29 JP JP2001553763A patent/JP2003520796A/ja active Pending
- 2000-12-04 PA PA20008508101A patent/PA8508101A1/es unknown
- 2000-12-27 CO CO00097877A patent/CO5271702A1/es not_active Application Discontinuation
-
2001
- 2001-01-17 US US09/761,994 patent/US6479513B2/en not_active Expired - Fee Related
- 2001-01-17 PE PE2001000041A patent/PE20011118A1/es not_active Application Discontinuation
- 2001-01-18 AR ARP010100227A patent/AR029792A1/es unknown
- 2001-01-18 GT GT200100008A patent/GT200100008A/es unknown
- 2001-01-19 TN TNTNSN01009A patent/TNSN01009A1/fr unknown
- 2001-01-19 MY MYPI20010243A patent/MY126069A/en unknown
- 2001-01-22 SV SV2001000291A patent/SV2002000291A/es not_active Application Discontinuation
-
2007
- 2007-07-18 JP JP2007186597A patent/JP2007326868A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02007153A (es) | 2002-12-13 |
| AU2001214087A1 (en) | 2001-07-31 |
| GT200100008A (es) | 2001-10-19 |
| WO2001053289A1 (en) | 2001-07-26 |
| TNSN01009A1 (fr) | 2005-11-10 |
| US6479513B2 (en) | 2002-11-12 |
| US20020004514A1 (en) | 2002-01-10 |
| SV2002000291A (es) | 2002-07-16 |
| PA8508101A1 (es) | 2002-08-26 |
| JP2003520796A (ja) | 2003-07-08 |
| CA2398353A1 (en) | 2001-07-26 |
| CA2398353C (en) | 2007-07-31 |
| EP1248782A1 (en) | 2002-10-16 |
| JP2007326868A (ja) | 2007-12-20 |
| MY126069A (en) | 2006-09-29 |
| HN2000000266A (es) | 2001-05-21 |
| BR0016986A (pt) | 2002-10-08 |
| CO5271702A1 (es) | 2003-04-30 |
| AR029792A1 (es) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011118A1 (es) | (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto | |
| UY26391A1 (es) | Inhibidores sglt2 de glucosidos de c-arilo y metodo | |
| CO5700767A2 (es) | Procedimiento de tratamiento de rechazo de transplantes | |
| DK0682664T3 (da) | Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler | |
| BG108225A (en) | Thiohydantoins and use thereof for treating diabetes | |
| AR038563A1 (es) | Composicion de ziprasidona y controles sinteticos | |
| BRPI0412975A (pt) | espuma penetrante para uso farmacêutico | |
| AR020345A1 (es) | Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones. | |
| AR051446A1 (es) | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) | |
| UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
| CR6592A (es) | Compuestos para el tratamiento de la isquemia | |
| MX2007006397A (es) | Derivados de tetrahidropirano. | |
| MXPA02005173A (es) | Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. | |
| WO2005016883A3 (en) | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof | |
| HRP20050510A2 (en) | Microbicide substances | |
| CA2334257A1 (en) | Treatment of osteoporosis with ep2/ep4 receptor selective agonists | |
| UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
| GR3020355T3 (en) | Aminosulfonyl urea acat inhibitors | |
| AP2004003106A0 (en) | Synergistic insecticidal mixtures. | |
| BR0316086A (pt) | N-sulfonil-4-metileno amino-3-hidróxi-2-piridonas como agente microbicida | |
| GB0326633D0 (en) | Therapeutic agents | |
| AU2001238332A1 (en) | Method of sterilizing articles | |
| WO2002041831A3 (en) | Inositol derivatives for increasing chloride secretion and inhibiting inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |